The company had applied for the authorization of ZyCoV-D last July 1, based on an efficacy rate of 66.6 percent in a late-stage trial of more than 28,000 volunteers nationwide.
Shirkaddu waxay codsatay oggolaanshaha ZyCoV-D bishii Luulyo 1, iyada oo ku saleysan heerka wax-ku-oolnimada ee 66.6 boqolkiiba tijaabadii dambe ee in ka badan 28,000 mutadawiciin ah oo dalka oo dhan ah.